NYSE:NVRO - Nevro Stock Price, Forecast & News

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro Corp (NYSE:NVRO) released its quarterly earnings data on Wednesday, November, 6th. The medical equipment provider reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.27. The medical equipment provider had revenue of $100.16 million for the quarter, compared to analysts' expectations of $92.27 million. Nevro had a negative net margin of 25.94% and a negative return on equity of 46.35%. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.37) earnings per share. View Nevro's Earnings History.

Nevro is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Nevro.

Nevro issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $114.4-114.4 million, compared to the consensus revenue estimate of $109.73 million.

12 Wall Street analysts have issued 12 month price objectives for Nevro's stock. Their forecasts range from $65.00 to $144.00. On average, they anticipate Nevro's stock price to reach $99.50 in the next year. This suggests that the stock has a possible downside of 20.3%. View Analyst Price Targets for Nevro.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

News coverage about NVRO stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nevro earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Nevro.

Nevro saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 2,870,000 shares, a decrease of 8.0% from the December 31st total of 3,120,000 shares. Based on an average daily volume of 401,800 shares, the days-to-cover ratio is presently 7.1 days. Approximately 9.7% of the shares of the company are sold short. View Nevro's Current Options Chain.

Some companies that are related to Nevro include Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD), Irhythm Technologies (IRTC), Glaukos (GKOS) and Merit Medical Systems (MMSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Incyte (INCY), Micron Technology (MU), Starbucks (SBUX), ABIOMED (ABMD), Celgene (CELG) and Intercept Pharmaceuticals (ICPT).

Nevro's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.04%), Campbell & CO Investment Adviser LLC (0.01%), Nkcfo LLC (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Exchange Traded Concepts LLC (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio, Campbell & CO Investment Adviser LLC, Nkcfo LLC, Exchange Traded Concepts LLC, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $124.85.

Nevro has a market capitalization of $3.87 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.

The official website for Nevro is http://www.nevro.com/.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]